Microbix Schedules Release of Results for Q4 Fiscal 2024
Microbix Schedules Release of Results for Q4 Fiscal 2024
Results Release and Webinar Discussion on Morning of December 19, 2024
2024年12月19日上午發佈結果並進行網絡研討會討論
MISSISSAUGA, Ontario, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its fourth quarter of fiscal 2024 ended September 30, 2024 ("Q4 2024") prior to the start of trading on December 19, 2024. At 11:00 AM ET on that day, Microbix intends to hold a webinar discussion of Q4 2024 results with its CEO, CFO, and COO.
加拿大安大略省密西沙加,2024年12月12日(全球資訊網)-- Microbix Biosystems Inc.(TSX: MBX,OTCQX: MBXBF,Microbix),一家生命科學創新公司、製造商和出口商,宣佈預計將在2024年12月19日交易開始前提交截至2024年9月30日的財務報表及管理層披露與分析(「2024財年第四季度」)。在那天的東部時間上午11:00,Microbix計劃與其首席執行官、首席財務官和首席運營官舉行關於2024財年第四季度結果的網絡研討會討論。
Investor and shareholders can participate in the webinar, hosted by Adelaide Capital, by registering at: .
投資者和股東可以通過註冊參加由阿德萊德資本主持的網絡研討會,註冊鏈接爲:.
It will also be live-streamed to YouTube at: .
它也將在YouTube上進行現場直播,鏈接爲:.
Telephone participation in the webinar can be arranged by contacting Microbix or Adelaide Capital at the contact numbers provided at the end of this news release.
通過聯繫Microbix或阿德萊德資本,可以安排電話參與網絡研討會,聯繫方式見本資訊發佈末尾。
A replay of the webinar will also be made available on Adelaide Capital's YouTube channel.
網絡研討會的重播將在阿德萊德資本的YouTube頻道上提供。
About Microbix Biosystems Inc.
Microbix Biosystems Inc. creates proprietary biological products for human health, with over 100 skilled employees and sales now targeting C$ 2.0 million per month. It makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.
關於Microbix Biosystems Inc.
Microbix Biosystems Inc. 爲盈健醫療創造專有生物產品,擁有超過100名技術熟練的員工,銷售額目前正瞄準每月200萬加元。它製造和出口各種關鍵成分和設備,爲全球診斷行業提供,特別是用於免疫測定的抗原及其實驗室質量評估產品(QAPs),這些產品支持臨床實驗室能力測試,促進檢測方法的開發和驗證,或幫助確保臨床診斷工作流程的質量。其抗原推動了約100個診斷製造商的抗體檢測,而QAPs則銷售給臨床實驗室認證組織、診斷公司和臨床實驗室。Microbix的QAPs目前已在30多個國家上市,並由國際分銷商網絡支持。Microbix擁有ISO 9001和13485認證,美國FDA註冊,澳大利亞TGA註冊,加拿大衛生部門註冊,並提供CE標記產品。
Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.
Microbix還利用其生物技術專長和基礎設施開發其他專有產品和技術,最著名的是Kinlytic尿激酶,這是一種用於治療血栓的生物溶栓藥物,以及支持分子診斷測試的試劑或培養基(例如,其DxTm用於患者樣本收集)。Microbix在TSX和OTCQX上市,總部位於加拿大安大略省密西沙加市。
Forward-Looking Information
This news release includes "forward-looking information," as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, expected timing of release of financial results, intended discussion of financial results or the outlook for the business, risks associated with its financial results and stability, its current or future products, development projects such as those referenced herein, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain, and that actual performance may be affected by many material factors, some of which are beyond the Company's control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company's judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.
前瞻性信息
本新聞稿包含「前瞻性信息」,該術語在適用證券法中有具體定義。前瞻性信息包括但不限於,財務結果發佈的預期時間,有關財務結果或業務前景的討論,財務結果和穩定性相關的風險,當前或未來的產品,如本文中提到的發展項目,向外國地區的銷售,工程和施工,生產(包括對成本、質量、數量和交付及時性的控制),外幣和匯率,維持充足的流動資金以及在可接受的條款下或根本不再融資的能力,以及其他類似的關於預計未來事件、條件或結果的陳述,這些結果並非歷史事實。這些陳述反映了管理層當前的估計、信念、意圖和期望;它們並不是對未來業績的保證。公司提醒,所有前瞻性信息本質上是不確定的,實際業績可能受到許多重要因素的影響,其中一些因素超出公司的控制範圍。因此,實際的未來事件、條件和結果可能與前瞻性信息中表達或暗示的估計、信念、意圖和期望有重大不同。所有陳述均基於本新聞稿日期,並代表公司在本新聞稿日期的判斷,公司沒有義務更新或更改任何前瞻性信息。
Please visit or for recent Microbix news and filings.
請訪問或以獲取最新的Microbix資訊和文件。
For further information, please contact Microbix at:
如需進一步信息,請聯繫Microbix:
Cameron Groome, CEO (905) 361-8910 |
Jim Currie, CFO (905) 361-8910 |
Deborah Honig, Investor Relations Adelaide Capital Markets (647) 203-8793 ir@microbix.com |
卡梅倫·格魯姆, 首席執行官 (905) 361-8910 |
吉姆·庫裏, 首席財務官 (905) 361-8910 |
黛博拉·霍尼格, 投資者關係 阿德萊德資本市場 (647) 203-8793 ir@microbix.com |
Copyright 2024 Microbix Biosystems Inc.
Microbix, DxTM, Kinlytic, & QAPs are trademarks of Microbix Biosystems Inc.
版權 2024 Microbix Biosystems Inc.
Microbix,DxTm,Kinlytic,& QAPs是Microbix Biosystems Inc.的商標。
譯文內容由第三人軟體翻譯。